Enorama Pharma AB (ERMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enorama Pharma AB (ERMA) has a cash flow conversion efficiency ratio of 0.631x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-14.79 Million ≈ $-1.59 Million USD) by net assets (Skr-23.45 Million ≈ $-2.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enorama Pharma AB - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Enorama Pharma AB for a breakdown of total debt and financial obligations.
Enorama Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enorama Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Income & Growth VCT
LSE:IGV
|
-0.017x |
|
Amedeo Air Four Plus Limited
LSE:AA4
|
0.270x |
|
BATHURST METALS CORP.
F:J1Q0
|
N/A |
|
GREEN SHIFT COMMODITIES
F:7WV
|
-0.042x |
|
Gibui Holdings Ltd
TA:GIBUI
|
-0.080x |
|
Vp plc
LSE:VP
|
0.245x |
|
CLARITY METALS CORP.
F:27G0
|
N/A |
|
Dragon Mountain Gold Ltd
AU:DMG
|
-0.204x |
Annual Cash Flow Conversion Efficiency for Enorama Pharma AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Enorama Pharma AB (ERMA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-23.45 Million ≈ $-2.52 Million |
Skr-59.26 Million ≈ $-6.38 Million |
2.527x | +155.23% |
| 2024-12-31 | Skr7.80 Million ≈ $839.73K |
Skr-35.70 Million ≈ $-3.84 Million |
-4.575x | -116.20% |
| 2023-12-31 | Skr19.54 Million ≈ $2.10 Million |
Skr-41.35 Million ≈ $-4.45 Million |
-2.116x | -102.43% |
| 2022-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-32.96 Million ≈ $-3.55 Million |
-1.045x | +25.99% |
| 2021-12-31 | Skr21.35 Million ≈ $2.30 Million |
Skr-30.16 Million ≈ $-3.25 Million |
-1.413x | +89.09% |
| 2020-12-31 | Skr1.78 Million ≈ $191.23K |
Skr-23.00 Million ≈ $-2.47 Million |
-12.942x | -249.80% |
| 2019-12-31 | Skr7.18 Million ≈ $772.64K |
Skr-26.56 Million ≈ $-2.86 Million |
-3.700x | -371.31% |
| 2018-12-31 | Skr17.02 Million ≈ $1.83 Million |
Skr-13.36 Million ≈ $-1.44 Million |
-0.785x | +13.32% |
| 2017-12-31 | Skr7.36 Million ≈ $792.18K |
Skr-6.67 Million ≈ $-717.43K |
-0.906x | -34.48% |
| 2016-12-31 | Skr9.08 Million ≈ $977.10K |
Skr-6.11 Million ≈ $-658.02K |
-0.673x | -1015.31% |
| 2015-12-31 | Skr6.52 Million ≈ $702.09K |
Skr480.00K ≈ $51.66K |
0.074x | -36.25% |
| 2014-12-31 | Skr2.66 Million ≈ $286.26K |
Skr307.00K ≈ $33.04K |
0.115x | -- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.